# Joe Beverly

> Joe Beverly is a pre-seed investor backing Medical and Marketing. See 3 investments, round sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Total investments: 3
- Last investment: Oct 2022
- Lead investor: 100%
- Last updated: Aug 2026

Joe Beverly is a pre-seed investor focused on Medical and Marketing. Joe Beverly

## Contacts

5 contacts available for Joe Beverly: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/joe-beverly?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 33% |
| Marketing | 1 | 33% |
| Advertising | 1 | 33% |
| Health Care | 1 | 33% |
| Life Science | 1 | 33% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Pre-Seed | 2 | 67% |
| Series A | 1 | 33% |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Lasarrus | Lasarrus develops devices for patients with chronic obstructive pulmonary disease. The company was founded in 2018 (incorporated in 2021) and is headquartered in Baltimore, Maryland. | $100K | Pre-Seed | Oct 03, 2022 |  |
| MooveGuru | MooveGuru focuses on consumers to the merchant they need when they need it. The company's services offer just-in-time delivery through artificial intelligence algorithms, enabling consumers to receive agent-branded savings from national and local retailers as they step through the relocation process. | $2.3M | Series A | Oct 30, 2019 |  |
| Lena Biosciences | Lena Biosciences is a biotechnology company offering advanced, organ-on-a-chip and 3D cell culture products for precision therapies, biomedical research and drug testing. Its new PerfusionPal product is a high-throughput organ-on-a-chip insert system that yields up to 5 times greater drug metabolism. It fits into existing workflows and enablescustomers to emulate multiple organs, deliver and test drugs in a standard format for ADME Tox screening, cancer research, and precision therapies. Owing to concentrated secretome and metabolome, PerfusionPal is ideally suited for testing slow-to-metabolize drugs and biologics (monoclonal antibodies and antibody-drug conjugates). |  | Pre-Seed | Oct 11, 2016 |  |

3 of 3 investments shown.

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Everywhere Ventures](https://shizune.co/investors/profile/everywhere-ventures) — VC Fund

## FAQ

### What does Joe Beverly invest in?

Joe Beverly invests primarily in Medical, Marketing and Advertising startups, most often at Pre-Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Joe Beverly?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Joe Beverly last invest?

The most recent investment recorded for Joe Beverly closed in Oct 2022. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co